ProCE Banner Activity

COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI

Slideset Download
Conference Coverage
In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.

Released: September 29, 2021

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Daiichi Sankyo Inc

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc